Compile Data Set for Download or QSAR
Report error Found 2309 Enz. Inhib. hit(s) with Target = 'Prolyl endopeptidase FAP'
TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622054(US20230312550, Example 14)
Affinity DataKon:  0.0000640M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622055(US20230312550, Example 15)
Affinity DataKoff:  4.90E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622055(US20230312550, Example 15)
Affinity DataKon:  0.0000460M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622141(US20230312550, Example 101)
Affinity DataKon:  0.0000250M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622142(US20230312550, Example 102)
Affinity DataKoff:  2.00E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622142(US20230312550, Example 102)
Affinity DataKon:  0.0000800M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622143(US20230312550, Example 103)
Affinity DataKoff:  3.00E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622143(US20230312550, Example 103)
Affinity DataKon:  0.000100M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622144(US20230312550, Example 104)
Affinity DataKoff:  3.00E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622144(US20230312550, Example 104)
Affinity DataKon:  0.0000610M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622145(US20230312550, Example 105)
Affinity DataKoff:  8.90E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622145(US20230312550, Example 105)
Affinity DataKon:  0.0000680M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622146(US20230312550, Example 106)
Affinity DataKoff:  1.80E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622146(US20230312550, Example 106)
Affinity DataKon:  0.000140M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622147(US20230312550, Example 107)
Affinity DataKoff:  1.90E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622054(US20230312550, Example 14)
Affinity DataKoff:  1.30E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622056(US20230312550, Example 16)
Affinity DataKoff:  7.40E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622056(US20230312550, Example 16)
Affinity DataKon:  0.0000410M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622057(US20230312550, Example 17)
Affinity DataKoff:  8.30E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622057(US20230312550, Example 17)
Affinity DataKon:  0.000120M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622041(US20230312550, Example 1 | (R)-N-(2-(4-Cyanothiazo...)
Affinity DataKoff:  7.30E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622193(US20230312550, Example 153)
Affinity DataKon:  0.0000850M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622194(US20230312550, Example 154)
Affinity DataKoff:  9.10E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622194(US20230312550, Example 154)
Affinity DataKon:  0.0000540M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622195(US20230312550, Example 155)
Affinity DataKoff:  3.10E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622195(US20230312550, Example 155)
Affinity DataKon:  0.0000500M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622196(US20230312550, Example 156)
Affinity DataKoff:  1.20E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622196(US20230312550, Example 156)
Affinity DataKon:  0.0000660M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622197(US20230312550, Example 157)
Affinity DataKoff:  1.90E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622197(US20230312550, Example 157)
Affinity DataKon:  0.000120M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622198(US20230312550, Example 158)
Affinity DataKoff:  3.10E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622198(US20230312550, Example 158)
Affinity DataKon:  0.000290M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622199(US20230312550, Example 159)
Affinity DataKoff:  2.10E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622199(US20230312550, Example 159)
Affinity DataKon:  0.0000920M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622200(US20230312550, Example 160)
Affinity DataKoff:  1.10E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622200(US20230312550, Example 160)
Affinity DataKon:  0.0000740M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622201(US20230312550, Example 161)
Affinity DataKoff:  1.40E+7s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622201(US20230312550, Example 161)
Affinity DataKon:  0.000280M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622202(US20230312550, Example 162)
Affinity DataKoff:  1.90E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622202(US20230312550, Example 162)
Affinity DataKon:  0.0000280M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622204(US20230312550, Example 164)
Affinity DataKoff:  1.40E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622204(US20230312550, Example 164)
Affinity DataKon:  0.0000360M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622205(US20230312550, Example 165)
Affinity DataKoff:  1.20E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622072(US20230312550, Example 32)
Affinity DataKoff:  1.30E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622215(US20230312550, Example 175)
Affinity DataKoff:  1.40E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622215(US20230312550, Example 175)
Affinity DataKon:  0.000120M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622216(US20230312550, Example 176)
Affinity DataKoff:  1.20E+5s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622174(US20230312550, Example 134)
Affinity DataKon:  0.0000800M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622175(US20230312550, Example 135)
Affinity DataKoff:  1.70E+6s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetProlyl endopeptidase FAP(Human)
Astrazeneca

US Patent
LigandPNGBDBM622175(US20230312550, Example 135)
Affinity DataKon:  0.0000230M-1s-1Assay Description:Table 1: Compounds were tested in a direct binding assay using 8K surface plasmon resonance biosensor (GE Healthcare) at 20° C. Immobilization of hFA...More data for this Ligand-Target Pair
In DepthDetails
US Patent

Displayed 1 to 50 (of 2309 total ) | Next | Last >>
Jump to: